Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/BD and EMS launch semaglutide therapy in Brazil with advanced injection pen for metabolic diseases

BDX

$167.47

+$1.13 +0.68%

BD and EMS launch semaglutide therapy in Brazil with advanced injection pen for metabolic diseases

Market News

29 Jul 2026

PRNewsWire

View Source

Bullish

BD (Becton, Dickinson and Company) and Brazil's EMS have partnered to launch a semaglutide therapy in Brazil targeting obesity and type 2 diabetes. The therapy uses BD's Vystra™ Injection Pen platform, designed for safe, accurate, and easy self-injection, addressing patient challenges in treatment adherence. This collaboration aims to expand access to advanced metabolic therapies in Brazil, leveraging BD's expertise in drug delivery and EMS's pharmaceutical reach. The partnership reflects a commitment to improving chronic disease management with scalable, patient-friendly solutions.

More News (BDX)

BD declares $1.05 quarterly dividend payable September 30, 2026.

BD (Becton, Dickinson and Company) announced a quarterly dividend of $1.05 per share, payable on September 30, 2026, to shareholders of record as of September 9, 2026. This dividend translates to an annual rate of $4.20 per share. BD is a leading glo...

Company Fundamentals

Neutral

21 hours ago